NEXSPIKE is Moderna’s third product to receive a positive CHMP opinion alongside Spikevax (COVID-19 Vaccine, mRNA) and ...
CAMBRIDGE, MA / ACCESS Newswire / June 12, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the U.S. Food and Drug Administration (FDA) has approved mRESVIA® (mRNA-1345), the Company’s ...
You recently posted a couple of articles about the respiratory syncytial virus (RSV) vaccine and the benefits versus the ...
The recommendation by the CHMP should now result in approval of Arexvy in the broader age range in February next year, and ...
In this article, we will be taking a look at the Top 10 AI-Powered Biotech Stocks to Buy Now. Moderna, Inc. is placed among them. Moderna, Inc. (NASDAQ:MRNA), a Cambridge-based biotechnology leader, ...
GSK said on Friday a panel of the European Medicines Agency had backed the use of its respiratory syncytial virus (RSV) vaccine, Arexvy, for all adults above the age of 18, paving the way for broader ...
Research led by the Veterans Affairs Portland Health Care System in Portland, Oregon, found that a single dose of respiratory ...
Moderna said Wednesday that its experimental mRNA-based seasonal flu vaccine generated a stronger immune response against four strains of the flu virus than a currently marketed vaccine in a Phase 3 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback